NetCompany has today won an important contract in Norway. Legemiddelverket (the Norwegian Medicines Agency) has awarded Netcompany a NOK 192m order for the development contract for a new IT platform. This is the company's first large contract in Norway, and is a landmark for the company. The order will improve utilisation from "today" in the Norwegian business and, once in operation, work as a reference client in the country. After several tenders where NetCompany apparently ended up #2 or #3, we consider this an important win. We maintain our combined DCF- and peer group-based valuation range of DKK 450-525 per share and leave our estimates unchanged. Marketing material commissioned by Netcompany.
LÄS MER
